产品收购

Search documents
Perimeter Solutions(PRM) - 2025 Q1 - Earnings Call Transcript
2025-05-08 13:30
Perimeter Solutions (PRM) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 Please note this call is being recorded and I will be standing by should you need any assistance. It is now my pleasure to turn today's program over to Seth Barker, Head of Investor Relations. Please go ahead. Speaker1 Thank you, operator. Good morning, everyone, and thank you for joining Perimeter Solutions' first quarter twenty twenty five earnings call. Speaking on today's call are Haytham Khoury, Chief Executive Officer an ...
Relmada Therapeutics(RLMD) - 2024 Q4 - Earnings Call Transcript
2025-03-28 00:07
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Brian Ritchie - LifeSci Advisors, IR Sergio Traversa - CEO Maged Shenouda - CFO Conference Call Participants Uy Ear - Mizuho Securities Andrew Tsai - Jefferies Operator Greetings, and welcome to the Relmada Therapeutics, Incorporated Quarter 4 2024 Financial Results Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal present ...
9.7亿收购韩国REGEN,爱美客将如何与江苏吴中对话?
IPO日报· 2025-03-17 11:45
星标 ★ IPO日报 精彩文章第一时间推送 近期, 爱美客技术发展股份有限公司(下称" 爱美客")发布公告,拟通过持股70%的子公司Imeik International Limited ( 下称" 爱美客国际" ) 收 购韩国REGEN Biotech,Inc.公司(下称"韩国REGEN")85%的股权,交易金额约为1.90亿美元(约合人民币13.86亿元)。 收购完成后,爱美客将持有韩国REGEN59.5%股权,将后者纳入合并报表。值得注意的是,由于 江苏吴中医药发展股份有限公司(下称" 江苏吴中") 拥有韩国REGEN 主要产品, 艾塑菲童颜针 在中国的独家代理权(有效期至2032年8月28日),这意味着,如果爱美客成功收购,它还将因代理权 的问题与江苏吴中打交道。 具体投资过程是,爱美客和首瑞香港分别出资70%和30%,成立了爱美客国际有限公司,作为本次交易的收购主体,股权穿透来看,爱美客实际花费1.33 亿美元(折合人民币9.7亿元)购买韩国REGEN公司59.5%股权,而公告中85%股权的剩余部分(约25.5%),则由首瑞香港出资0.57亿美元收购。 此外,公司还宣布,如果本次收购能够得到批准并完 ...